Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment
Completed · Phase 1
Conditions studied: Hepatitis C Virus
In brief
The primary objective of the study is to evaluate the single-dose pharmacokinetics (PK) of velpatasvir (formerly GS-5816) in participants with severe renal impairment using matched healthy participants as a control group.
Key facts
- Study ID
- NCT02002767
- Run by
- Gilead Sciences
- People needed
- 19
- Starts
- 2013-12-16
- Expected to finish
- 2014-06-09
- Last updated by the study team
- 2020-11-16
Who can join
Age: 18 and older, up to 79. Sex: any. Healthy volunteers: accepted.
Where it is running
- Study site — Miami, Florida, United States
- Study site — Orlando, Florida, United States
- Study site — Saint Paul, Minnesota, United States
- Study site — San Antonio, Texas, United States
- Study site — Christchurch, New Zealand
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.